Drug intelligence / Profile preview

quinolysine

Development stage: Unknown
Lead developer: Shanghai Institute of Materia Medica
Modality: Small Molecules
Administration: Oral

Overview

Quinolysine is a selective alpha-1A adrenergic receptor (α1A-AR) antagonist developed by the Shanghai Institute of Materia Medica (SIMM) of the Chinese Academy of Sciences. It is primarily being investigated for the treatment of benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS). By selectively blocking the α1A subtype, which is the predominant alpha-adrenergic receptor in the human prostate and bladder neck, quinolysine promotes smooth muscle relaxation to improve urinary flow. This high degree of selectivity is intended to provide therapeutic efficacy while minimizing systemic side effects, such as orthostatic hypotension, which are commonly associated with non-selective alpha-1 adrenergic antagonists.

Other names: 喹啉利辛

Targets

ADRA1A (α1A)

Beyond the preview

Go deeper on quinolysine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on quinolysine.

Explore the full profile